Targeting immunotherapy for bladder cancer using anti‐CD3× B7‐H3 bispecific antibody

Objective B7‐H3 is attractive for cancer immunotherapy with B7‐H3 overexpressed tumors. To explore whether B7‐H3 is an effective target for patients with bladder cancer, anti‐ CD 3× anti‐B7‐H3 bispecific antibodies (B7‐H3Bi‐Ab) was armed with activated T cells ( ATC ) to kill bladder cancer cells. Methods High expressions of B7‐H3 on human bladder cancer cells were detected, including Pumc‐91 and T24 cells, and their chemotherapeutic...